Juan M Racosta1,2, Luciano A Sposato1,2, Kurt Kimpinski1,2. 1. Department of Clinical Neurological Sciences, Room C7-131, University Hospital, London Health Sciences Centre, 339 Windermere Road, London, Ontario, Canada, N6A 5A5. 2. Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Abstract
INTRODUCTION: High-dose intravenous immunoglobulin (IVIg) is an evidence-based treatment for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Recently, subcutaneous immunoglobulin (SC-Ig) has received increasing attention. METHODS: We performed a meta-analysis of reports of efficacy and safety of SC-Ig versus IVIg for inflammatory demyelinating polyneuropathies. RESULTS: A total of 8 studies comprising 138 patients (50 with MMN and 88 with chronic CIDP) were included in the meta-analysis. There were no significant differences in muscle strength outcomes in MMN and CIDP with Sc-Ig (MMN: effect size [ES] = 0.65, 95% confidence interval [CI] = -0.31-1.61; CIDP: ES = 0.84, 95% CI = -0.01-1.69). Additionally SC-Ig had a 28% reduction in relative risk (RR) of moderate and/or systemic adverse effects (95% CI = 0.11-0.76). CONCLUSIONS: The efficacy of SC-Ig is similar to IVIg for CIDP and MMN and has a significant safety profile. Muscle Nerve 55: 802-809, 2017.
INTRODUCTION: High-dose intravenous immunoglobulin (IVIg) is an evidence-based treatment for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Recently, subcutaneous immunoglobulin (SC-Ig) has received increasing attention. METHODS: We performed a meta-analysis of reports of efficacy and safety of SC-Ig versus IVIg for inflammatory demyelinating polyneuropathies. RESULTS: A total of 8 studies comprising 138 patients (50 with MMN and 88 with chronic CIDP) were included in the meta-analysis. There were no significant differences in muscle strength outcomes in MMN and CIDP with Sc-Ig (MMN: effect size [ES] = 0.65, 95% confidence interval [CI] = -0.31-1.61; CIDP: ES = 0.84, 95% CI = -0.01-1.69). Additionally SC-Ig had a 28% reduction in relative risk (RR) of moderate and/or systemic adverse effects (95% CI = 0.11-0.76). CONCLUSIONS: The efficacy of SC-Ig is similar to IVIg for CIDP and MMN and has a significant safety profile. Muscle Nerve 55: 802-809, 2017.
Authors: Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk Journal: Cochrane Database Syst Rev Date: 2017-01-13
Authors: D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette Journal: J Neurol Date: 2020-04-28 Impact factor: 4.849
Authors: Ivo N van Schaik; Orell Mielke; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Billie L Durn; David R Cornblath; Ingemar S J Merkies Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-07-03